key: cord-0760940-2dwnw1qd authors: Mahmoud, D. S.; Ibrahim, M. E.; Thakre, D. B.; Teddy, D. J. G.; Raheja, M. P.; Ganesan, D. S.; Zaher, D. W. title: Evaluation of pooling of samples for testing SARS-COV- 2 for mass screening of COVID-19 date: 2021-03-24 journal: nan DOI: 10.1101/2021.03.15.21253567 sha: 1587c17a708c8b6ab03d1d2296bac9ad8e3e96ce doc_id: 760940 cord_uid: 2dwnw1qd Abstract Background The current pandemic of SARS- COV- 2 virus, widely known as COVID-19 has affected millions of people around the world. The World Health Organization (WHO) has recommended vigorous testing to differentiate SARS-CoV-2 from other respiratory infections to aid in guiding appropriate care and management. Situations like this have demanded robust testing strategies and pooled testing of samples for SARS- COV- 2 virus has provided the solution to mass screening of people. The pooled testing strategy can be very effective in testing with limited resources, yet it comes with its own limitations. These limitations need critical consideration when it comes to testing of highly infectious disease like COVID -19. Methods The study evaluated the pooled testing of nasopharyngeal swabs for SARS- COV- 2 by comparing sensitivity of individual sample testing with 4 and 8 pool sample testing. Median cycle threshold (Ct) values were compared. The precision of pooled testing was assessed by doing an inter and intra assay of pooled samples. Coefficient of variance was calculated for inter and intra assay variability. Results The sensitivity becomes considerably low when the samples are pooled, there is a higher percentage of false negatives with higher pool size and when the patient viral load is low or weak positive samples. High variability was seen in the intra and inter assay, especially in weak positive samples and larger pool size. Conclusion As COVID - 19 numbers are still high and testing capacity needs to be high, we have to meticulously evaluate the testing strategy for each country depending on its testing capacity, infrastructure, economic strength, and need to make a serious call on cost effective strategy of resource saving and risk/ cost of missing positive patients. The sensitivity becomes considerably low when the samples are pooled, there is a higher 26 percentage of false negatives with higher pool size and when the patient viral load is low or 27 weak positive samples. High variability was seen in the intra and inter assay, especially in weak 28 positive samples and larger pool size. 29 Conclusion 30 As COVID -19 numbers are still high and testing capacity needs to be high, we have to 31 meticulously evaluate the testing strategy for each country depending on its testing capacity, 32 infrastructure, economic strength, and need to make a serious call on cost effective strategy of 33 resource saving and risk/ cost of missing positive patients. what is known the virus seems to exhibit a variable incubation period which can be up to 14 40 days and asymptomatic carriers can also transmit the virus, it spreads rapidly and affected large 41 number of people than SARS and MERS, despite having lower case fatality rate. 1 All these 42 characteristics of the novel virus has made the containment and control of the virus challenging. 43 The World Health Organization (WHO) has recommended robust diagnostic testing to 44 differentiate SARS-CoV-2 from other respiratory infections to aid in guiding appropriate care 45 and management. Since the pandemic has affected millions of people, mass testing requires a 46 lot of resources. Further the WHO has suggested around 10 -30 tests per Positive case as a 47 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 24, 2021. ; https://doi.org/10.1101/2021.03.15.21253567 doi: medRxiv preprint 3 benchmark for adequate testing, it also has recommended a positive rate lower than 10% and 48 better if lower than 3%. 2 In situations like this sample pooling can be a vital strategy to do testing in large numbers, 50 where sample extracts from a random number of samples from a heterogeneous population 51 group are combined into a single tube for pooled PCR analysis and this strategy have shown to 52 be cost-effective during mass testing compared with individual testing. 3 When the disease prevalence is less, it can be advantageous to pool individual samples into a 54 single pool, this increases the test capacity and reduces the number of PCR tests. 4 Figure 1 ]. With this background, the study aims to evaluate the pooling strategy for mass 71 screening of COVID-19. The aim of the study is to evaluate the pooling method for mass screening of COVID-19. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in If "S" shaped fluorescence curve is detected with a FAM Ct > 35, re-extraction is done and RT 96 PCR test is repeated, if a negative result is detected, it is reported negative and if "S" curve is 97 detected with a FAM Ct ≤ 38 in re extraction results, then a positive report is given. To assess the precision of pooled sample method intra and inter assay precision study were 113 conducted. Intra assay precision 115 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Our study showed that the sensitivity of 4 pooled sample was 75% and the sensitivity of 8 133 pooled sample was 62.5% (Table 1 and table 2 ). The sensitivity decreases from 75% in 4 pool 134 sampling to 62.5% in 8 pool sampling. In the low viral load, weak positive samples (Ct value 135 ≥ 35), sensitivity of 4 pool sample was 50% (Table 3) and it further reduces to 25% in 8 pool 136 sampling with a false negative percentage as high as 75%. (Table 4) 137 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The Ct difference was calculated between individual and pooled sample and the difference 138 increased with the increase in pool size, the difference was more pronounced in the low viral 139 load, weak positive group. (Table 5 ). The median Ct difference increased with increase in pool (Table 148 7 and Table 8 ) testing. 14 A study in UK, has strongly supported pooled approach and reports a clinically perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The study also showed that the pooling resulted in a median loss of 2.29 Ct for high viral load perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Coronavirus: covid-19 has killed more people than SARS and 254 MERS combined, despite lower case fatality rate Simulation of pool sampling analysis strategy for 259 COVID -19 mass testing Sample pooling as a strategy to detect community 262 transmission of SARS-CoV-2 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 24, 2021. ; https://doi.org/10.1101/2021.03.15.21253567 doi: medRxiv preprint